KYNB

4/A - KYNTRA BIO, INC. (0000921299) (Issuer)

4 - KYNTRA BIO, INC. (0000921299) (Issuer)

10-Q - KYNTRA BIO, INC. (0000921299) (Filer)

8-K - KYNTRA BIO, INC. (0000921299) (Filer)

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis anticipated in 4Q 2026 Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC were presented at ASCO GU in February 2026, further validating key Phase 2 monotherapy design elements Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden is being finalized following feedback from the U.S. Food and Drug Admi

SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (NASDAQ:KYNB) will announce first quarter 2026 financial results on Monday, May 11 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationKyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone,

DEFA14A - KYNTRA BIO, INC. (0000921299) (Filer)

DEF 14A - KYNTRA BIO, INC. (0000921299) (Filer)

8-K - KYNTRA BIO, INC. (0000921299) (Filer)

SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB) today announced that the Company will present at the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026. Thane Wettig, Chief Executive Officer of Kyntra Bio, will deliver a company presentation on Monday, April 13, 2026, at 1:30 PM EDT. A live webcast of the presentation will be available here. Kyntra Bio's management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at Needham. A replay of the presentation will be posted, when available, to the Kyntra Bio website on the Events & Presentations page of the Inves

10-K - KYNTRA BIO, INC. (0000921299) (Filer)

8-K - KYNTRA BIO, INC. (0000921299) (Filer)

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and remains on track for interim analysis in 2H 2026Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC, further validating key Phase 2 monotherapy design elements, were presented at the 2026 ASCO GUSubmitted the pivotal Phase 3 clinical trial protocol for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden to the U.S. Food and Drug AdministrationCash, cash

4 - KYNTRA BIO, INC. (0000921299) (Issuer)

4 - KYNTRA BIO, INC. (0000921299) (Issuer)

SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB), formerly FibroGen (NASDAQ:FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationKyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the con

FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic progression free survival (rPFS) of 7.0 months in the overall study cohort, with median rPFS of 10.1 months observed in patients who progressed on only one prior ARPIHigher tumor uptake of FG-3180, a CD46 directed PET imaging agent, demonstrated a trend towards higher probability of PSA50 response, highlighting its potential for patient selection Combination therapy had a similar safety and exposure profile to the previous FG-3246 Phase 1 monotherapy trialResul

SAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB), formerly FibroGen (NASDAQ:FGEN), today announced that the company's management will participate in the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFormat: Corporate Presentation Date & Time: Thursday, February 26, 2026, 2:40-3:10 PM ET Location: Virtual Webcast: https://event.summitcast.com/view/ Leerink Global Healthcare ConferenceFormat: Corporate Presentation Date & Time: Wednesday, March 11, 2026, 2:20-2:50 PM ETLocation: Miami, FL Webcast: https://event.summitcast.com/view/ Kyntra Bio's management team will be available for one-on-one meetings during the confere

4 - KYNTRA BIO, INC. (0000921299) (Issuer)

4 - KYNTRA BIO, INC. (0000921299) (Issuer)